949PMirvetuximab soravtansine, a folate receptor alpha (FRα)-targeting antibody-drug conjugate (ADC), with pembrolizumab in platinum-resistant ovarian cancer (PROC): Initial results of an expansion cohort from FORWARD II, a phase Ib study. (23rd October 2018) - Matulonis, U A; Moore, K N; Martin, L P; Vergote, I B; Castro, C; Gilbert, L; Malek, K; Birrer, M J; O'Malley, D M